Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures

被引:53
作者
Weichold, FF
Zella, D
Barabitskaja, O
Maciejewski, JP
Dunn, DE
Sloand, EM
Young, NS
机构
[1] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA
[2] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA
[3] NHLBI, Hematol Branch, Bethesda, MD 20892 USA
关键词
D O I
10.1182/blood.V91.3.907.907_907_915
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Attempts to clarify the pathophysiology of human immunodeficiency virus (HIV)-mediated bone marrow (BM) dysfunction have yielded inconsistent results regarding the susceptibility of BM progenitors to the viral infection. To specifically address this question, we exposed highly purified subpopulations of human BM progenitor cells to various HIV-1 and HIV-2 strains and assessed (pro)viral gene presence and expression in more-committed (CD34(+)CD38(+)) as well as most-primitive (CD34(+)CD38(-)) cells in long-term BM cultures. Quantitative analysis of long-term culture-initiating cells (LTCIC) failed to demonstrate adverse effects of exposing hematopoietic stem cells to HIV. Our results show that HIV-2, similar to HIV-1, does not infect hematopoietic stem cells in vitro with any significant frequency and infected cells are not present within LTCICs. Cytofluorometric analysis of CD34(+) cells for surface molecules that facilitate HIV entry was consistent with the functional assay in that expression of virus receptors was predominantly on the more-committed subsets of BM progenitors. The failure to detect productive or latent HIV in the most-primitive human BM progenitor and stem cells has important implications for future therapeutic strategies, including those dealing with transduction of these cells with protective genes as a treatment modality for AIDS. (C) 1998 by The American Society of Hematology.
引用
收藏
页码:907 / 915
页数:9
相关论文
共 57 条
  • [1] AROCK M, 1994, CELL MOL BIOL, V40, P319
  • [2] BAGNARA GP, 1990, EXP HEMATOL, V18, P426
  • [3] CALENDA V, 1994, EUR J HAEMATOL, V52, P103
  • [4] CALENDA V, 1995, EUR J HAEMATOL, V54, P180
  • [5] CALENDA V, 1992, J ACQ IMMUN DEF SYND, V5, P1148
  • [6] SUSCEPTIBILITY OF HUMAN BONE-MARROW STROMAL CELLS TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)
    CANQUE, B
    MARANDIN, A
    ROSENZWAJG, M
    LOUACHE, F
    VAINCHENKER, W
    GLUCKMAN, JC
    [J]. VIROLOGY, 1995, 208 (02) : 779 - 783
  • [7] CEN D, 1993, BRIT J HAEMATOL, V85, P596, DOI 10.1111/j.1365-2141.1993.tb03353.x
  • [8] IN-VITRO HUMAN IMMUNODEFICIENCY VIRUS-1 INFECTION OF PURIFIED HEMATOPOIETIC PROGENITORS IN SINGLE-CELL CULTURE
    CHELUCCI, C
    HASSAN, HJ
    LOCARDI, C
    BULGARINI, D
    PELOSI, E
    MARIANI, G
    TESTA, U
    FEDERICO, M
    VALTIERI, M
    PESCHLE, C
    [J]. BLOOD, 1995, 85 (05) : 1181 - 1187
  • [9] Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry
    Chen, ZW
    Zhou, P
    Ho, DD
    Landau, NR
    Marx, PA
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (04) : 2705 - 2714
  • [10] The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
    Cocchi, F
    DeVico, AL
    GarzinoDemo, A
    Cara, A
    Gallo, RC
    Lusso, P
    [J]. NATURE MEDICINE, 1996, 2 (11) : 1244 - 1247